U.S., April 10 -- ClinicalTrials.gov registry received information related to the study (NCT06918808) titled 'DB-3Q bmMSC-EVs in Patients With Perianal Fistulizing Crohn's Disease' on April 02.
Brief Summary: This is a double-blind, randomized, placebo-controlled, sequential cohort, ascending dose clinical trial to evaluate the safety and determine the efficacy of ascending doses of DB-3Q for the treatment of Perianal Fistulizing Crohn's Disease.
Study Start Date: April 15
Study Type: INTERVENTIONAL
Condition:
Perianal Fistula Due to Crohn's Disease
Intervention:
BIOLOGICAL: DB-3Q
DB-3Q (IMP) is the frozen liquid formulation of acellular secretome proteins and extracellular vesicles isolated from human bmMSC and processed under ...